# LLIN Evaluation in Uganda Project (LLINEUP2) – Effect of longlasting insecticidal nets (LLINs) treated with pyrethroid plus pyriproxyfen vs LLINs treated with pyrethroid plus piperonyl butoxide in Uganda: a cluster-randomised trial

Samuel Gonahasa<sup>1,7</sup>\* Jane Frances Namuganga<sup>1</sup>, Martha J Nassali<sup>1</sup>, Catherine Maiteki Sebuguzi<sup>1,2</sup>, Isaiah Nabende<sup>1</sup>, Adrienne Epstein<sup>3</sup>, Katherine Snyman<sup>1,4,5</sup>, Joaniter I Nankabirwa<sup>1,6</sup>, Jimmy Opigo<sup>2</sup>, Martin J Donnelly<sup>7,8</sup>, Grant Dorsey<sup>3</sup>, Moses R Kamya <sup>1,6</sup>, Sarah G Staedke<sup>5,7,9</sup>

- Infectious Diseases Research Collaboration, Uganda
- National Malaria Control Division, Ministry of Health, Uganda
- <sup>3</sup> Department of Medicine, University of California San Francisco, USA
- Department of Global Health and Development, London School of Hygiene & Tropical Medicine
- Department of Clinical Research, London School of Hygiene & Tropical Medicine, UK
- <sup>6</sup> Department of Medicine, Makerere University, Kampala, Uganda
- Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK
- 8 Wellcome Sanger Institute, Hinxton, UK
- <sup>9</sup> Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

**Corresponding author:** Samuel Gonahasa, Infectious Diseases Research Collaboration, PO Box 7475, Kampala, Uganda; Email: <a href="mailto:samuelgonahasa@gmail.com">samuelgonahasa@gmail.com</a>; Tel: +256 (0) 772 833471

#### Samuel Gonahasa MBChB MSc

PhD Fellow/Investigator, Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda samuelgonahasa@gmail.com

#### Jane F Namuganga MD MHS

Project Coordinator
Infectious Diseases Research Collaboration
2C Nakasero Hill Road, Kampala, Uganda
inamuganga@idrc-uganda.org

## Martha J Nassali MBChB MPH

Survey Coordinator Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda mnassali@idrc-uganda.org

# Catherine Maiteki-Sebuguzi MBChB MSc

Principal Medical Officer Policy and Strategy National Malaria Control Division Uganda Ministry of Health, Kampala, Uganda cmaiteki@gmail.com

#### Isaiah Nabende BSc

Data Manager
Infectious Disease Research Collaboration
2C Nakasero Hill Road, Kampala, Uganda
inabende@idrc-uganda.org

## Adrienne Epstein PhD

Post-Doctoral Research Associate
Department of Medicine
University of California, San Francisco
San Francisco, CA 94110 USA
adrienne.epstein@ucsf.edu

#### Katherine Snyman MPH

PhD student, LSHTM
Research Associate
Infectious Diseases Research Collaboration
2C Nakasero Hill Road, Kampala, Uganda
Katherine.snyman@lshtm.ac.uk

#### Joaniter I Nankabirwa MBChB PhD

Lecturer

Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda jnankabirwa@yahoo.co.uk

#### Jimmy Opigo MBChB MPH

Assistant Commissioner Health Services Manager, National Malaria Control Division Uganda Ministry of Health, Kampala, Uganda opigojimmy@gmail.com

## Martin J Donnelly PhD ScD

Professor of Evolutionary Genetics Liverpool School of Tropical Medicine Pembroke Place, Liverpool L3 5QA, UK martin.donnelly@lstmed.ac.uk

## **Grant Dorsey MD MPH PhD**

Professor of Medicine
Department of Medicine
University of California, San Francisco
San Francisco, CA 94110 USA
grant.dorsey@ucsf.edu

## Moses R Kamya MBChB MMed MPH PhD

Professor of Medicine
Department of Medicine,
Makerere University College of Health
Sciences
Infectious Diseases Research Collaboration
2C Nakasero Hill Road, Kampala, Uganda
mkamya@infocom.co.ug

#### Sarah G Staedke MD PhD

Professor of Malaria & Global Health Department of Vector Biology Liverpool School of Tropical Medicine Liverpool UK sarah.staedke@lstmed.ac.uk

## Abstract

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Background. We embedded a pragmatic, cluster-randomised trial into Uganda's national campaign to distribute long-lasting insecticidal nets (LLINs) in 2020–2021, comparing LLINs treated with pyrethroids plus the synergist piperonyl butoxide (PBO), to LLINs treated with pyrethroids plus pyriproxyfen, an insect growth regulator. Methods. Target communities surrounding public health facilities (clusters, n=64), covering 32 highburden districts not receiving indoor residual spraying, were included. Clusters were randomised 1:1 in blocks of two by district to receive: (1) pyrethroid-PBO LLINs (PermaNet 3.0, n=32) or (2) pyrethroid-pyriproxyfen LLINs (Royal Guard, n=32). LLINs were delivered from 7 November 2020 to 26 March 2021 and malaria outcome data were collected until 31 March 2023. Estimates of malaria incidence in residents of all ages (the primary outcome) were generated for each cluster from enhanced health facility surveillance data. At 12- (24 November 2021 to 1 April 2022) and 24-months (23 November 2022 to 21 March 2023) post-LLIN distribution, cross-sectional community surveys were conducted in randomly selected households (at least 50 per cluster, 3,200 per survey). **Findings.** In the two years following LLIN distribution, 186,364 episodes of malaria were diagnosed in cluster residents during 398,931 person-years of follow-up. Malaria incidence after 24-months was lower than at baseline in both arms (pyrethroid-PBO: 465 vs 676 episodes per 1000 person-years; pyrethroid-pyriproxyfen: 469 vs 674 episodes per 1000 person-years); but the difference between the arms was not statistically significant (incidence rate ratio 1.06, 95% confidence interval [CI] 0.91-1.22, p=0.47). Two years post-distribution, ownership of at least one LLIN for every two household residents was low in both arms (41.1% pyrethroid-PBO vs 38.6% pyrethroid-pyriproxyfen). Parasite prevalence in children aged 2-10 years was no different between the arms in either survey and similar results were observed for prevalence of anaemia in children aged 2-4 years. Interpretation. The effectiveness of pyrethroid-PBO LLINs and pyrethroid-pyriproxyfen LLINs was no different in Uganda, but two years after mass distribution, LLIN coverage was inadequate.

Funding. US National Institutes for Health, Bill and Melinda Gates Foundation

Trial registration

NCT04566510. Registered 28 September 2020, <a href="https://clinicaltrials.gov/ct2/show/NCT04566510">https://clinicaltrials.gov/ct2/show/NCT04566510</a>

Keywords

malaria, long-lasting insecticidal nets (LLINs), insecticide treated nets (ITNs), piperonyl butoxide,

PermaNet 3.0, pyriproxyfen, Royal Guard, cluster-randomised trial, Uganda

Word count = 4,782

# Introduction

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Between 2000 and 2015, intensified efforts to control malaria substantially reduced malaria case incidence and parasite prevalence across Africa, with the majority of cases averted attributed to the distribution of long-lasting insecticidal nets (LLINs) [1]. More recently, however, progress on malaria control has stalled. Globally, malaria cases increased from 230 million in 2015 to 247 million in 2021, with 95% of cases reported from Africa [2]. Four African countries, including Uganda, accounted for nearly half of all cases worldwide in 2021. In Uganda, implementation of malaria control interventions including repeated national LLIN distribution campaigns, case management with effective artemisinin-based combination therapy, and indoor residual spraying (IRS) of insecticides in selected high-transmission districts reduced the malaria burden, with parasite prevalence by microscopy in children under-five decreasing from 45% in 2009 to 9% in 2018-2019 [3]. Progress in malaria control in Uganda has been difficult to sustain, however, despite ongoing implementation of effective control interventions [4, 5]. In Uganda, and across Africa, LLINs are the most widely-used malaria prevention tool [6]. As recommended by the World Health Organization (WHO), the Ugandan Ministry of Health distributes LLINs through mass campaigns approximately every three years, aiming for universal coverage [7]. Currently, LLINs rely on pyrethroid insecticides, but resistance to pyrethroids has spread rapidly in malaria vectors, threatening the effectiveness of LLINs [2, 8]. The causal mechanisms of pyrethroid resistance are complex, but point mutations in the voltage-gated sodium channel where pyrethroids bind ('knock down resistance'), and alterations in enzymes that metabolize pyrethroids, commonly cytochrome P450s, are key features [9, 10]. To combat emerging resistance, next generation LLINs that incorporate a second chemical in addition to pyrethroids have been developed. One such net includes piperonyl butoxide (PBO), a synergist which inhibits P450 enzymes, overcoming metabolic resistance mechanisms in mosquitoes,

5

and partially restoring susceptibility to pyrethroids [11, 12]. Supported by evidence from trials conducted in Tanzania and Uganda [13-15], demonstrating the superiority of pyrethroid-PBO LLINs over pyrethroid-only LLINs, the WHO endorsed deployment of pyrethroid-PBO LLINs in areas where malaria vectors exhibit pyrethroid resistance. The WHO's recommendation was conditional due to uncertainty about the cost-effectiveness and durability of pyrethroid-PBO LLINs [16, 17]. Another new type of LLIN combines pyrethroids with pyriproxyfen, an insect growth regulator which acts as a sterilising agent, reducing the vector population density and lifespan of adult mosquitoes. Pyrethroid-pyriproxyfen LLINs are promising, but trials comparing these nets to pyrethroid-only LLINs in Burkina Faso and Tanzania have produced mixed results [18, 19]. Additional studies evaluating the effectiveness of nets incorporating pyriproxyfen are needed. In 2020-2021, two next generation LLINs including pyrethroid-PBO LLINs and pyrethroidpyriproxyfen LLINs were distributed in Uganda, providing an opportunity to evaluate the effectiveness of these LLINs in a 'real-world' setting. With support from the Ministry of Health, donors, and partners, a large cluster-randomised trial (LLINEUP2) was embedded within this national distribution campaign, allowing us to rigorously compare the impact of these LLINs on epidemiological indicators. We aimed to test the hypothesis that malaria incidence would be lower in intervention clusters (randomised to receive pyrethroid-pyriproxyfen LLINs) than in control clusters (randomised to receive pyrethroid-PBO LLINs). Malaria surveillance data at health facilities were collected between 17 October 2020 and 31 March 2023, and cross-sectional community survey data between 24 November 2021 to 1 April 2022 (12-months) and 23 November 2022 to 21 March 2023 (24-months) post-LLIN distribution.

# Methods

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

# Study setting

Districts with high malaria burden were selected to participate in the study (figure 1) if they were not receiving IRS and were scheduled to receive pyrethroid-PBO LLINs. A cluster was defined as the target area surrounding public health facilities with enhanced malaria surveillance, known as Malaria Reference Centres (MRCs) [20]. MRCs are high-volume, level III or IV health centres with an estimated outpatient department attendance of 1,000–3,000 patients per month and a functional laboratory. To avoid contamination, MRCs within the same district were selected from different subcounties. Overall, 64 clusters located in 32 districts were included in the trial.

## Assignment of interventions

#### Cluster definition

The unit of randomisation (cluster) was the 'target area' surrounding each MRC. Target areas had an estimated population of at least 1,200 residents and included the MRC's village plus adjacent villages without another health facility, located within the same sub-county as the MRC village, and with similar malaria incidence as the MRC village. All households within the target areas were mapped and enumerated to determine the population and to generate a sampling frame for community surveys.

# Cluster randomisation

Clusters were randomised in a 1:1 ratio to receive either pyrethroid-PBO LLINs (PermaNet 3.0, Vestergaard Sàrl, Switzerland), or pyrethroid-pyriproxyfen LLINs (Royal Guard, Disease Control Technologies, USA). Randomisation was carried out by a member of the study team based outside of Uganda at the University of California, San Francisco, who had no direct links to the net distribution team at the Ministry of Health in Uganda. To improve comparability between arms, MRCs were selected in each district for allocation to the intervention and control arm in a matched pair-wise fashion. Clusters were randomised in blocks of two, with each block representing a district

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

containing two clusters, using the 'runiform' command in STATA version 14.2 (StataCorp, Texas, USA). **LLIN** distribution LLINs were delivered free-of-charge through a mass distribution campaign led by the Ugandan Ministry of Health and partners from 7 November 2020 to 26 March 2021. Members of the research team engaged with Uganda's national committees that coordinated the campaign, to ensure that LLINs were allocated according to the randomisation scheme. For each cluster we used a 'fried egg' approach (figure 1); LLINs were delivered to the entire sub-county, including the MRC and several other villages beyond the MRC target area ('egg white'), while outcomes were measured in the MRC target areas ('egg yolk'). Nets were distributed from house-to-house, targeting all households within the subcounty and aiming for population level coverage of at least 85%. Health facility-based surveillance At each MRC, individual-level data for all patients recorded into standardised outpatient department registers were entered into an Access database by on-site data entry officers. Primary data captured included location of residence (parish and village), age, gender, temperature, history of fever, type of malaria test done, malaria test results, diagnoses given, and any treatments prescribed. Data from each MRC was submitted to the research team monthly using a secure on-line system. Data captured from 1 November 2019 to 31 March 2023 was used to generate estimates of malaria incidence. Cross-sectional surveys Cross-sectional community surveys were conducted 12-months (24 November 2021 to 1 April 2022) and 24-months (23 November 2022 to 21 March 2023) after nets were distributed. A study team, consisting of a clinician and research assistant carried out the surveys. Households were randomly

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

selected from the enumeration lists for each cluster and screened until 50 households with at least one child aged 2-10 years was enrolled from each cluster (with a total of 64 clusters, leading to at least 3,200 households per survey). If an enrolled household had no children of appropriate age, they were included in the household survey only, but did not take part in the clinical survey. Households were included if at least one adult aged 18 years or older was present, the adult was usually resident and slept in the household on the night before the survey, and the adult provided informed consent. Households were excluded if the house had been destroyed or could not be found, the house was vacant, or no adult resident was home on more than three occasions. A household questionnaire adapted from prior surveys, including the national Malaria Indicator Survey, was administered to the head of the household (or their designate), after obtaining their consent, using a hand-held tablet computer. Information was gathered on the characteristics of households and residents, proxy indicators of wealth including ownership of assets, and ownership and use of LLINs in the households. All children aged 2–10 years from enrolled households were eligible for the clinical survey if they were usually resident and present in the household on the night before the survey, their parent or guardian provided informed consent, and the child provided assent if they were aged 8 years or older. Children not home on day of survey were excluded. The clinical surveys included measurement of temperature, subjective fever, and a finger-prick blood sample for preparation of thick blood smears, and haemoglobin measurement (in children aged 2-4 years). Participants with a temperature of >38.0°C, or who reported fever in the past 48h, had a rapid diagnostic test (RDT) done (Bioline Malaria Ag P.f/Pan, Abbott Diagnostics, Inc). Participants with a positive RDT were treated with artemether-lumefantrine, or referred if they had evidence of severe disease. Any participants with a haemoglobin <7.0 g/dL or other concerning clinical symptoms were referred for further management.

#### Laboratory procedures

Thick blood smears obtained in the cross-sectional surveys were dried and transported to the Infectious Diseases Research Collaboration Molecular Research Laboratory in Kampala within seven days for processing and reading. Slides were stained with 3% Giemsa for 30 minutes and read by experienced laboratory technologists. Parasite densities were calculated by counting the number of asexual parasites, per 200 leukocytes (or per 500, if the count was less than 10 parasites per 200 leukocytes), assuming a leukocyte count of 8,000/µl. A thick blood smear was considered negative when the examination of 100 high power fields did not reveal asexual parasites. For quality control, all slides were read by a second microscopist and a third reviewer settled discrepant readings, defined as (1) positive versus a negative thick blood smear, (2) parasite density differing by ≥25%. Haemoglobin measurements were made using a portable HemoCue analyzer (HemoCue, Ängelholm, Sweden).

## **Outcome measures**

The primary outcome of the trial was cumulative incidence of symptomatic malaria cases in cluster residents of all ages captured at the MRCs over the 24 months following LLIN distribution. The total number of malaria cases for each cluster was determined from the number of laboratory-confirmed malaria cases diagnosed at the MRC in patients residing within the target area, over the two-year follow-up period, correcting for cluster residents with suspected malaria seen at the MRC who did not undergo laboratory testing, and for patients with laboratory-confirmed malaria whose village of residence was unknown (due to missing data). The population of the MRC target area determined in the enumeration surveys was used as the denominator for incidence calculations for each cluster with a constant growth factor of 0.29% per month, derived from the UN Department of Economic

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

and Social Affairs Population Division World Population Prospects data (https://population.un.org/wpp/), which estimated an annual growth rate of 3.46% in 2019 (divided by 12 for the monthly rate of 0.29%). Secondary outcomes for the cross-sectional community surveys included LLIN ownership (the proportion of households that owned at least one LLIN), adequate LLIN coverage (the proportion of households that owned at least one LLIN for every two occupants), LLIN use (the proportion of household residents who reported sleeping under an LLIN the previous night), prevalence of parasitaemia (in children aged 2-10 years), and prevalence of anaemia (in children aged 2-4 years). Sample size calculations Our sample size of 32 clusters per arm was calculated to detect a 26% difference (incidence rate ratio [IRR] = 0.74) in malaria incidence between the two study arms over the 24 months following LLIN distribution (the primary endpoint of the study), given a power of 80% and a two-sided significance level of 0.05, assuming an incidence of 332 malaria cases per 1,000 person-years in the control arm and a coefficient of variation of 0.42, which was calculated from the 14 MRCs where estimates of malaria incidence over 6 months were available at the time of protocol development. For the cross-sectional community surveys, we planned to sample all eligible children aged 2-10 years from 50 households in the 64 clusters in each survey. Assuming an average of 1.8 children aged 2-10 years per household, we estimated that 5,760 children from 3,200 households would be included. Assuming a coefficient of variation of 0.40, across a wide range of prevalence measures in the control arm (10-70%), our sample size allowed us to detect a 25-28% difference in the prevalence measure of interest, equivalent to a prevalence ratio of 0.72-0.75, given a power of 80% and a two-sided significance level of 0.05.

Analytical issues

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

All analyses were conducted using an intention-to-treat approach. We compared cluster-level estimates of the incidence of malaria between the intervention (pyrethroid-pyriproxyfen LLINs) and the control arm (pyrethroid-PBO LLINs) using a mixed effects Poisson regression model with a random effect at the district level (each district included two clusters, randomised to one of the two study arms) and adjustment for log-transformed estimates of the baseline malaria incidence (three months prior to the intervention) for each cluster. The effect of the intervention was expressed as an incidence rate ratio (incidence in the intervention arm/incidence in the control arm). For the cross-sectional surveys, separate analyses were conducted 12- and 24-month following LLIN distribution. Houses were classified as 'modern' (synthetic walls and roofs, eaves closed or absent) or 'traditional' (all other construction). We compared individual level estimates of the prevalence of parasitaemia and anaemia between the intervention (pyrethroid-pyriproxyfen LLINs) and the control arm (pyrethroid-PBO LLINs) using a mixed effects logistic regression model with random effects at the level of the cluster and household. We compared household-level estimates of LLIN ownership, coverage, and use with a mixed effects logistic regression model with a random effect at the level of the cluster. Effects of the intervention were expressed as odds ratios (odds in the intervention arm/odds in the control arm).

## Research ethics approval and participant consent

The research included in this trial was conducted under two study protocols. The Implementation Project Pilot Study covered enumeration of the target areas and estimation of malaria incidence using health facility surveillance data. This project was approved by the Makerere University School of Medicine Research & Ethics Committee (SOMREC, Ref 2019-087), the Ugandan National Council of Science and Technology (UNCST, Ref HS 2659), and the University of California, San Franciso Human Research Protection Program Institutional Review Board (UCSF Ref 19-27957).

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

The LLINEUP2 trial protocol provided approval for the full trial, including the cross-sectional surveys, and was approved by the Makerere University School of Medicine Research & Ethics Committee (SOMREC Ref 2020-193), Ugandan National Council for Science and Technology (UNCST Ref HS1097ES), the University of California San Francisco Human Research Protection Program Institutional Review Board (UCSF Ref 20-31769), and the London School of Hygiene & Tropical Medicine Ethics Committee (LSHTM Ref 22615). Prior to enrolment into the clinical surveys, written informed consent was obtained from a parent or guardian for all children aged less than 18 years and the child provided assent if they were aged 8 years or older. Results Characteristics of clusters, households, and residents Of the 64 clusters (figure 2), 32 were randomised to receive pyrethroid-PBO LLINs, and 32 to receive pyrethroid-pyriproxyfen LLINs. At baseline, the median estimated population of the clusters (MRC target areas) was 3,070 (range 1,084 — 5,915) in the pyrethroid-PBO LLIN arm, and 2,493 (range 756—8,663) in the pyrethroid-pyriproxyfen LLIN arm. Cross-sectional community surveys were carried out in all clusters (table 1) at 12-months (24 November 2021 to 1 April 2022) and 24-months (23 November 2022 to 21 March 2023) post-LLIN distribution. Characteristics of households enrolled in both surveys were similar across study arms (12-months: n=3,518, median 53 per cluster, range 50<sup>®</sup>78; 24-months: n=3,372, median 52 per cluster, range 50264). In both surveys, over half of households had three or more persons per sleeping room (55.8%) and were constructed of traditional materials (57.1%). Overall, 7,781 bed nets were surveyed at 12-months, and 6,306 at 24-months (table 1). Most nets (86.1%) were obtained in

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

the most recent universal coverage campaign (UCC), and nearly all nets (96.1%) were obtained for free. In total, 16,189 household residents were surveyed at 12-months, and 16,706 at 24-months (table 1); over half of residents were women (54.5%). In both surveys, the age distribution of residents was similar across the study arms. Children aged 2-10 years enrolled in the clinical survey (figure 2) were tested for parasitaemia (12-months: n=4,893, median 73 per cluster, range 54@122; 24-months: n=4,519, median 68 per cluster, range 50194). Children aged 2-4 years were tested for anaemia (12months: n=2,087, median 31 per cluster, range 17\( \tilde{D} 48; 24-months: n=1,908, median 30 per cluster, range 14248). LLIN delivery LLINs were delivered in the study area by the Ministry of Health and partners from 7<sup>th</sup> November 2020 to 26<sup>th</sup> March 2021. In total, 1,329,273 LLINs were allocated for distribution to the sub-counties surrounding each cluster, including 632,359 pyrethroid-pyriproxyfen LLINs and 696,914 pyrethroid-PBO LLINs. A cross-sectional survey was conducted in April-May 2021 in 12 clusters from 12 selected districts to evaluate the impact of the LLIN distribution campaign. As previously reported, [21] 1-5 months after LLIN distribution, household LLIN ownership was high. Of 634 households surveyed, 609 (96.1%) owned at least one LLIN. However, only 360 (56.8%) households owned at least one UCC LLIN for every 2 residents, while 374 (59.0%) were adequately covered by LLINs of any type. Impact on primary outcome: malaria incidence In the three months prior to completion of LLIN distribution (baseline), 32,384 episodes of malaria were diagnosed in residents of the clusters (MRC target areas) over 47,945 per-years of follow-up (table 2, figure 3). The baseline incidence of malaria in the two study arms was similar (676 episodes

14

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

per 1,000 person-years in the pyrethroid-PBO LLIN arm, and 674 episodes per person-year in the pyrethroid-pyriproxyfen LLIN arm). In the first 4 months following LLIN distribution, malaria incidence decreased in both study arms, but began to increase again 5-months post-distribution (figure 3). Overall, in the two years after LLIN distribution, 186,364 episodes of malaria were diagnosed in cluster residents during 398,931 person-years of follow-up (table 2). The incidence of malaria post-LLIN distribution was lower than baseline in both study arms (465 episodes per 1000 person-years in the pyrethroid-PBO arm, and 469 episodes per person-year in the pyrethroidpyriproxyfen arm), but the difference between the two arms was not statistically significant (incidence rate ratio (IRR) 1.06, 95% confidence interval (CI) 0.91-1.22, p2=20.47). Impact on secondary outcomes: LLIN ownership, coverage and use Trends in LLIN ownership, coverage and use were similar in both study arms at 12-months and 24months (table 3). Most households reported owning at least one LLIN at 12-months (91.9% pyrethroid-PBO vs 89.9% pyrethroid-pyriproxyfen), but ownership dropped at 24-months in both study arms (82.5% pyrethroid-PBO vs 80.0% pyrethroid-pyriproxyfen). In contrast, adequate coverage of LLINs (one LLIN for every two residents) was low at 12-months (59.9% pyrethroid-PBO vs 56.6% pyrethroid-pyriproxyfen) and fell even further at 24-months (41.1% pyrethroid-PBO vs 38.6% pyrethroid-pyriproxyfen). Similarly, although most household residents reported sleeping under a LLIN the previous night (74.2% pyrethroid-PBO vs 76.1% pyrethroid-pyriproxyfen); reported use of LLINs dropped at 24-months (63.6% pyrethroid-PBO vs 61.6% pyrethroid-pyriproxyfen). Impact on secondary outcomes: parasite prevalence and anaemia prevalence Parasite prevalence in children aged 2-10 years was no different in the two study arms at 12-months and 24-months post-LLIN distribution (table 3). Parasite prevalence at 12-months was 21.6% in the pyrethroid-PBO arm vs 26.4% in the pyrethroid-pyriproxyfen arm (odds ratio [OR] 1.49 [95% CI:

0.88–2.51], p=0.14). Similar results were observed at the 24-month timepoint (26.1% in the pyrethroid-PBO arm vs 29.5% in the pyrethroid-pyriproxyfen arm (OR 1.29 [95% CI: 0.81–2.05], p=0.29). The prevalence of anaemia (haemoglobin < 11 g/dL) in children aged 2-4 years decreased substantially between 12-months and 24-months, but there was no difference between the study arms at the two timepoints (table 3). Anaemia prevalence at 12-months was 36.2% in the pyrethroid-PBO arm vs 34.0% in the pyrethroid-pyriproxyfen arm (OR 0.88 [95% CI: 0.57–1.34], p=0.44). At 24-months, prevalence anaemia dropped to 19.7% in the pyrethroid-PBO arm vs 19.0% in the pyrethroid-pyriproxyfen arm (OR 0.95 [95% CI: 0.62–1.46], p=0.81).

# Costing of LLINs

We originally planned to conduct a cost-effectiveness analysis of the two LLINs studied, but given the lack of difference in LLIN effectiveness, we limited our assessment to a costing exercise. When the study LLINs were purchased (in 2019), the pyrethroid-pyriproxyfen LLINs (Royal Guard, \$2.28 USD per net) were slightly less expensive than the pyrethroid-PBO LLINs (PermaNet 3.0, \$2.51 USD per net). As of April 2023, market prices of the pyrethroid-pyriproxyfen LLINs were \$0.77 USD lower per net than pyrethroid-PBO LLINs (\$2.30 USD for Royal Guard vs \$3.07 USD for PermaNet 3.0) [22].

# **Discussion**

In this pragmatic, cluster-randomised trial embedded into Uganda's 2020–2021 LLIN distribution campaign, we compared the impact of two next generation LLINs on malaria incidence across 32 districts in Uganda. Despite a marked reduction in malaria incidence following LLIN distribution in both study arms, there was no difference in malaria incidence among residents of all ages, parasite prevalence among children 2-10 years of age, or anaemia prevalence among children 2-4 years of age from clusters that received pyrethroid-pyriproxyfen LLINs compared to those that received pyrethroid-PBO LLINs. Given the lack of difference in effectiveness of the two LLINs studied, we did

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

not conduct a cost-effectiveness analysis as originally planned. Faced with similar effectiveness, the choice of LLIN should be guided by price and other factors. Importantly, LLINs will only be effective if coverage is high, and nets are used. Two years post-distribution, we found only around 40% of households were adequately covered by LLINs, while just over 60% of residents reported sleeping under a LLIN the previous night. Pyrethroid-PBO LLINs were superior to pyrethroid-only LLINs in two trials conducted in east Africa, including the original LLINEUP trial in Uganda [13-15]. A Cochrane systematic review incorporating both trials concluded that pyrethroid-PBO LLINs reduced parasite prevalence compared to pyrethroid-only LLINs up to 21–25 months post-distribution (OR 0.79 [95% CI 0.67–0.95]), in areas with highly pyrethroid-resistant mosquitoes (defined as < 30% mosquito mortality in discriminating dose assays) [12]. Based on this evidence, the WHO issued a conditional recommendation in 2022 supporting the deployment of pyrethroid-PBO LLINs instead of pyrethroid-only LLINs in areas with ongoing malaria transmission where the principal malaria vector(s) exhibit pyrethroid resistance' [16]. However, pyrethroid-PBO LLINs have several potential limitations. Widespread pyrethroid resistance has been reported in Uganda [23, 24], and across Africa, with both knock-down and metabolic resistance described across several settings [11]. PBO is a synergist, not an insecticide, and can only restore sensitivity to pyrethroid insecticides if resistance is due to specific metabolic mechanisms. Moreover, PBO may fail to overcome high-level pyrethroid resistance [25]. Questions about the bioefficacy, durability, and lifespan of PBO-pyrethroid LLINs have also been raised [12, 16], given concerns about the rapid degradation of PBO from nets raised by studies conducted in Kenya and Tanzania [26, 27]. In Uganda, an evaluation of nets distributed in the first LLINEUP trial found that while the pyrethroid content of LLINs was relatively stable, the PBO content fell significantly over two years; by 55% in Olyset Plus and 58% in PermaNet 3.0 [17]. The bioefficacy of the pyrethroid-PBO nets also declined over time with only 46% and 79% of mosquitoes knocked down by Olyset Plus and PermaNet 3.0, respectively, after 25 months [17]. The WHO has highlighted the

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

need for further research on the effectiveness of pyrethroid-PBO LLINs, specifically in areas of lower transmission intensity and where pyrethroid resistance is not driven by cytochrome P450 metabolism, as well as on the durability and cost-effectiveness of pyrethroid-PBO LLINs [16]. Treating LLINs with a combination of insecticides with different modes of action may improve efficacy and help to prevent or delay the spread of insecticide resistance. Pyriproxyfen is an insect growth regulator, which has traditionally been used as a larvicide [28], but also acts as a sterilising agent, reducing the fecundity (egg laying), fertility (production of viable offspring), and longevity of adult mosquitoes [29]. Pyriproxyfen has a different mechanism of action than pyrethroids, is effective at very low concentrations, and is safe in humans [28]. In a step-wedge, cluster-randomised trial conducted in Burkina Faso, pyrethroid-pyriproxyfen LLINs (Olyset Duo) were associated with lower clinical incidence in children aged 6-59 months, and lower entomological inoculation rates than pyrethroid-only LLINs (Olyset Net) [18]. More recently, a cluster-randomised trial conducted in Tanzania evaluated three next generation LLINs, including LLINs treated with pyrethroidpyriproxyfen, pyrethroid-PBO, and pyrethroid-chlorfenapyr (a novel pyrrole insecticide), comparing their effect on parasite prevalence measured by RDT in children aged 6 months to 14 years, as compared to pyrethroid-only LLINs [19]. In this trial, parasite prevalence at 24 months postdistribution in the pyrethroid-pyriproxyfen LLIN arm was no different than in the pyrethroid-PBO control arm (37.5% vs 45.8%, adjusted OR 0.79 [95% CI 0.54-1.17]). Similarly, a cluster-randomised trial conducted in Benin studied pyrethroid-pyriproxyfen and pyrethroid-chlorfenapyr LLINs, as compared to pyrethroid-only LLINs, evaluating their effect on malaria incidence in children aged 6 months to 10 years [30]. This study also found no difference between the pyrethroid-pyriproxyfen and pyrethroid-only LLINs over 2 years following distribution (0.84 vs 1.03 malaria cases per childyear, hazard ratio 0.86 [95% CI 0.65-1.14]). In both trials, only the pyrethroid-chlorfenapyr LLINs were superior to the pyrethroid-only LLINs after two years [19, 30].

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

In March 2023, the WHO updated the guidelines on use of LLINs, supported by the recent results of the trials in Tanzania and Benin, offering a conditional recommendation for the deployment of pyrethroid-pyriproxyfen LLINs instead of pyrethroid-only LLINs in areas with pyrethroid resistance, and highlighting concerns about the cost-effectiveness of the pyrethroid-pyriproxyfen LLINs [16]. In addition, the WHO issued a conditional recommendation against the deployment of pyrethroidpyriproxyfen LLINs instead of pyrethroid-PBO LLINs, noting that the evidence favours pyrethroid-PBO LLINs which were also deemed more cost-effective than pyriproxyfen LLINs. The LLINEUP2 trial adds to the evidence of the effectiveness of pyrethroid-pyriproxyfen LLINs, but calls into guestion the recent WHO recommendations, given that the pyrethroid-pyriproxyfen LLINs (Royal Guard, Disease Control Technologies, USA) were less expensive than pyrethroid-PBO (PermaNet 3.0, Vestergaard Sàrl, Switzerland) LLINs in our trial (\$2.30 USD for Royal Guard vs \$3.07 USD for PermaNet 3.0) [22], with similar effectiveness. LLIN prices fluctuate, however, so this finding should not be generalised; whichever net has a lower market price on a given day will be the most cost-effective. Malaria incidence was the primary outcome measure of the LLINEUP2 trial, which was a strength of the study. Incidence of malaria, defined as the number of symptomatic cases of malaria occurring in a population at risk over time, is considered the gold standard for assessing malaria burden. However, cluster-randomised trials aiming to measure malaria incidence can be very expensive and logistically challenging. In this trial, we leveraged a platform of enhanced health facility-based malaria surveillance, which was built and supported by the Ugandan Malaria Surveillance Project [31]. Although routinely collected health facility-based data are often limited by incomplete reporting and lack of laboratory-confirmation, our enhanced health facility-based surveillance system acts as an intervention, improving data quality, ensuring nearly all cases of malaria are laboratory-confirmed, and improving case management. Moreover, by defining target areas around MRCs, collecting data on village of residence of malaria, and enumerating the target area populations to determine denominators, we estimated longitudinal measures of malaria incidence at

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

an unprecedented scale across Uganda, at relatively low cost. Embedding large-scale, clusterrandomised trials into Uganda's national LLIN distribution campaigns has provided an innovative, robust method to effectively evaluate next generation LLINs at scale, an exercise which would otherwise be very costly. This design provides a new paradigm for trials evaluating the 'real-world' effectiveness of malaria control interventions. This study had several limitations. First, due to resource limitations, entomologic surveillance and assessments of LLIN bioefficacy and durability were not conducted. Second, we were not able to survey the clusters prior to LLIN distribution, again due to lack of resources, and thus have no baseline measures of LLIN coverage, parasite prevalence or anaemia. However, MRC surveillance activities were ongoing for at least three months prior to LLIN distribution, providing baseline measures of malaria incidence for all clusters. Third, although no difference in prevalence of anaemia in children aged 2-4 years was observed between the pyrethroid-pyriproxyfen and pyrethroid-PBO arms at the 12- and 24-month timepoints, anaemia prevalence dropped markedly in both arms between the two surveys (pyrethroid-pyriproxyfen 34.0% to 19.0%; pyrethroid-PBO 36.2% to 19.7%). Reasons for this change are unclear but likely relate to variation around the threshold cut-off for anaemia (haemoglobin < 11 g/dL) and the complex aetiology of anaemia. Although malaria is a major cause of anaemia in endemic areas, other factors contribute including nutritional status, helminths and other infections, and health system factors. Our results suggest that pyriproxyfen-pyrethroid LLINs could be an effective alternative to pyrethroid-PBO LLINs in Uganda. Rotation of insecticides, including deployment of LLINs treated with different insecticides, has been recommended as a strategy to manage insecticide resistance [32]. Supported by the recent trials in Tanzania and Benin, the WHO has also issued new guidelines on LLINs treated with chlorfenapyr, offering a strong recommendation for the deployment of pyrethroid-chlorfenapyr LLINs instead of pyrethroid-only LLINs, and a conditional recommendation

for deployment of pyrethroid-chlorfenapyr LLINs instead of pyrethroid-PBO LLINs in areas where malaria vectors are resistant to pyrethroids. However, the evidence supporting these new recommendations is limited and further research on the effectiveness, durability and lifespan of next generation LLINs is needed. To address the continuing challenge of insecticide resistance, we are conducting another cluster-randomised trial (LLINEUP3) embedded with the 2023 universal coverage campaign in collaboration with the Ugandan MOH. This study is comparing the effectiveness of pyrethroid-chlorfenapyr LLINs versus pyrethroid-PBO LLINs in 24 clusters located in 20 districts in Uganda.

455 456

457

458

459

460

461

462

463

464 465

466

467

468

469

470

471

472 473

474

475 476

477

478

479

480 481

482

483

484

485

486

487

**ACKNOWLEDGEMENTS** We would like to thank Emmanuel Arinaitwe, James Kapisi, Chris Ebong, Bridget Nzarubara, Faith Kagoya, Emmanuel Bakashaba, Isiko Joseph, Paul Oketch, Benjamin Guma, Jolly Job Odongo, Daniel Ochuli, Geoffrey Omia, Leuben Patrick Okello, Geoff Lavoy, Peter Mutungi, Nicholas Wendo, Yasin Kisambira, Catherine Pitt and the administration of the Infectious Diseases Research Collaboration for all their contributions. We would also like to acknowledge and thank the members of the Uganda National Malaria Control Division and the Liverpool School of Tropical Medicine for logistical and other support rendered as we carried out the data collection and analysis. We are grateful to the district administration, health and political leadership teams for all their support and guidance during community engagement in the 32 districts of the study area. **AUTHORS' CONTRIBUTIONS** SGS, GD, MRK, MJD, SG, CMS, JIN and JO conceived and designed the study. SGS, GD, MRK, JIN, SG, JFN and CMS developed the procedures and drafted the protocol. SG, JFN, MJN, KS and IN collected the data, with oversight from SGS and MRK. IN and GD managed the data. GD, SG, KS, and SGS analysed the data. JIN, AE, MJD and MRK advised on the analysis. SG, JFN, MJN, DG and SGS drafted the manuscript. All authors reviewed the manuscript, provided input and approved the final version for publication. **DECLARATION OF INTERESTS** The authors declare that they have no competing interests. **FUNDING STATEMENT** This project was funded primarily by the US National Institutes for health, with additional funding from the Bill and Melinda Gates Foundation. The content of the manuscript is solely the responsibility of the authors. **DATA SHARING STATEMENT** De-identified participant data and a data dictionary defining each field in the set will be made publicly available at the time of publication on the ClinEpiDB website (https://clinepidb.org). A link to the statistical analysis for the primary outcome has also been provided on the ClinEpiDB website (https://clinepidb.org/ce/app/workspace/analyses/DS 624583e93e/5My0liA/visualizations/1fd2ff57 -954e-4c58-bf39-ebb113cc5a70).

489 REFERENCES 490 1) Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria 491 control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 492 2015;526(7572):207-11. doi: 10.1038/nature15535. PubMed PMID: 26375008. 493 2) World Health Organization. World Malaria Report 2022. Geneva: World Health Organization, 494 2022 Contract No.: ISBN 978-92-4-006490-4. 495 3) Uganda National Malaria Control Division (NMCD), Uganda Bureau of Statistics (UBOS), ICF. 496 Uganda Malaria Indicator Survey 2018-19. Kampala, Uganda, and Rockville, Maryland, USA 2020. 497 4) Namuganga JF, Epstein A, Nankabirwa JI, Mpimbaza A, Kiggundu M, Sserwanga A, et al. The 498 impact of stopping and starting indoor residual spraying on malaria burden in Uganda. Nat 499 Commun. 2021;12(1):2635. Epub 2021/05/13. doi: 10.1038/s41467-021-22896-5. PubMed 500 PMID: 33976132; PubMed Central PMCID: PMCPMC8113470. 501 5) Epstein A, Maiteki-Sebuguzi C, Namuganga JN, Nankabirwa JI, Gonahasa S, J. O, et al. Resurgence 502 of malaria in Uganda despite sustained indoor residual spraying and repeated long lasting 503 insecticidal net distributions. PLOS Global Public Health. 2022. doi: 504 https://doi.org/10.1371/journal.pgph.0000676. 505 6) Pryce J, Richardson M, Lengeler C. Insecticide-treated nets for preventing malaria. Cochrane Database Syst Rev. 2018;11:CD000363. doi: 10.1002/14651858.CD000363.pub3. PubMed PMID: 506 507 30398672. 508 7) World Health Organization. Achieving and maintaining universal coverage with long-lasting 509 insecticidal nets for malaria control Geneva: World Health Organisation, Global Malaria 510 Programme, 2017 Contract No.: WHO/HTM/GMP/2017.20. 511 Ranson H. Lissenden N. Insecticide Resistance in African Anopheles Mosquitoes: A Worsening 512 Situation that Needs Urgent Action to Maintain Malaria Control. Trends Parasitol. 513 2016;32(3):187-96. doi: 10.1016/j.pt.2015.11.010. PubMed PMID: 26826784. 514 9) Weetman D, Wilding CS, Neafsey DE, Muller P, Ochomo E, Isaacs AT, et al. Candidate-gene based 515 GWAS identifies reproducible DNA markers for metabolic pyrethroid resistance from standing 516 genetic variation in East African Anopheles gambiae. Scientific reports. 2018;8(1):2920. doi: 10.1038/s41598-018-21265-5. PubMed PMID: 29440767; PubMed Central PMCID: 517 518 PMCPMC5811533. 519 10) Njoroge H, Van't Hof A, Oruni A, Pipini D, Nagi SC, Lynd A, et al. Identification of a rapidly-520 spreading triple mutant for high-level metabolic insecticide resistance in Anopheles gambiae 521 provides a real-time molecular diagnostic for antimalarial intervention deployment. Molecular 522 ecology. 2022;31(16):4307-18. Epub 2022/07/02. doi: 10.1111/mec.16591. PubMed PMID: 523

35775282; PubMed Central PMCID: PMCPMC9424592.

524 11) Lynd A, Gonahasa S, Staedke SG, Oruni A, Maiteki-Sebuguzi C, Hancock PA, et al. LLIN Evaluation 525 in Uganda Project (LLINEUP)-effects of a vector control trial on Plasmodium infection prevalence 526 and genotypic markers of insecticide resistance in Anopheles vectors from 48 districts of 527 Uganda. Scientific reports. 2024;14(1):14488. Epub 20240624. doi: 10.1038/s41598-024-65050-528 z. PubMed PMID: 38914669; PubMed Central PMCID: PMCPMC11196729. 529 12) Gleave K, Lissenden N, Chaplin M, Choi L, Ranson H. Piperonyl butoxide (PBO) combined with 530 pyrethroids in insecticide-treated nets to prevent malaria in Africa. Cochrane Database Syst Rev. 531 2021;5(5):Cd012776. Epub 2021/05/25. doi: 10.1002/14651858.CD012776.pub3. PubMed PMID: 532 34027998; PubMed Central PMCID: PMCPMC8142305. 533 13) Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD, et al. Effectiveness of 534 a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray 535 interventions, separately and together, against malaria transmitted by pyrethroid-resistant 536 mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. Lancet. 537 2018;391(10130):1577-88. doi: 10.1016/S0140-6736(18)30427-6. PubMed PMID: 29655496; 538 PubMed Central PMCID: PMCPMC5910376. 539 14) Staedke SG, Gonahasa S, Dorsey G, Kamya MR, Maiteki-Sebuguzi C, Lynd A, et al. Effect of long-540 lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda 541 (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution 542 campaign. Lancet. 2020;395(10232):1292-303. Epub 2020/04/20. doi: 10.1016/S0140-543 6736(20)30214-2. PubMed PMID: 32305094; PubMed Central PMCID: PMCPMC7181182. 544 15) Maiteki-Sebuguzi C, Gonahasa S, Kamya MR, Katureebe A, Bagala I, Lynd A, et al. Effect of long-545 lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda 546 (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution 547 campaign. Lancet Infect Dis. 2023;23(2):247-58. Epub 2022/09/30. doi: 10.1016/S1473-548 3099(22)00469-8. PubMed PMID: 36174592. 549 16) World Health Organization. Guidelines for malaria. Geneva: World Health Organization, 2023 14 550 March 2023. Report No.: Contract No.: WHO/UCN/GMP/2023.01. 551 17) Mechan F, Katureebe A, Tuhaise V, Mugote M, Oruni A, Onyige I, et al. LLIN evaluation in Uganda 552 project (LLINEUP): The fabric integrity, chemical content and bioefficacy of long-lasting 553 insecticidal nets treated with and without piperonyl butoxide across two years of operational 554 use in Uganda. Curr Res Parasitol Vector Borne Dis. 2022;2:100092. Epub 2022/06/24. doi: 555 10.1016/j.crpvbd.2022.100092. PubMed PMID: 35734077; PubMed Central PMCID: 556 PMCPMC9207544. 557 18) Tiono AB, Ouedraogo A, Ouattara D, Bougouma EC, Coulibaly S, Diarra A, et al. Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against 558 559 clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-560 randomised controlled trial. Lancet. 2018;392(10147):569-80. Epub 2018/08/15. doi: 561 10.1016/S0140-6736(18)31711-2. PubMed PMID: 30104047.

10.1010/30140-0730(18)31711-2. Publiked Pikilb. 30104047.

562 19) Mosha JF, Kulkarni MA, Lukole E, Matowo NS, Pitt C, Messenger LA, et al. Effectiveness and cost-563 effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal 564 nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised 565 trial. Lancet. 2022;399(10331):1227-41. Epub 2022/03/28. doi: 10.1016/S0140-6736(21)02499-566 5. PubMed PMID: 35339225; PubMed Central PMCID: PMCPMC8971961. 567 20) Nankabirwa JI, Rek J, Arinaitwe E, Namuganga JF, Nsobya SL, Asua V, et al. East Africa 568 International Center of Excellence for Malaria Research: Summary of Key Research Findings. Am 569 J Trop Med Hyg. 2022;107(4 Suppl):21-32. Epub 2022/10/14. doi: 10.4269/ajtmh.21-1285. 570 PubMed PMID: 36228916; PubMed Central PMCID: PMCPMC9294681. 571 21) Okiring J, Gonahasa S, Nassali M, Namuganga JF, Bagala I, Maiteki-Sebuguzi C, et al. LLIN 572 Evaluation in Uganda Project (LLINEUP2)-Factors associated with coverage and use of longlasting 573 insecticidal nets following the 2020-21 national mass distribution campaign: a cross-sectional 574 survey of 12 districts. Malar J. 2022;21(1):293. Epub 2022/10/20. doi: 10.1186/s12936-022-575 04302-7. PubMed PMID: 36261818; PubMed Central PMCID: PMCPMC9580445. 576 22) The Global Fund to Fight AIDS TB and Malaria. Workbook: Price & Quality Reporting Transaction 577 Summary (theglobalfund.org), 2023. 578 23) Mawejje HD, Wilding CS, Rippon EJ, Hughes A, Weetman D, Donnelly MJ. Insecticide resistance 579 monitoring of field-collected Anopheles gambiae s.l. populations from Jinja, eastern Uganda, 580 identifies high levels of pyrethroid resistance. Medical and veterinary entomology. 581 2013;27(3):276-83. doi: 10.1111/j.1365-2915.2012.01055.x. PubMed PMID: 23046446; PubMed 582 Central PMCID: PMC3543752. 583 24) Mawejje HD, Weetman D, Epstein A, Lynd A, Opigo J, Maiteki-Sebuguzi C, et al. Characterizing 584 pyrethroid resistance and mechanisms in Anopheles gambiae (s.s.) and Anopheles arabiensis 585 from 11 districts in Uganda. Curr Res Parasitol Vector Borne Dis. 2023;3:100106. Epub 586 2023/01/03. doi: 10.1016/j.crpvbd.2022.100106. PubMed PMID: 36590346; PubMed Central 587 PMCID: PMCPMC9798136. 588 25) Riveron JM, Huijben S, Tchapga W, Tchouakui M, Wondji MJ, Tchoupo M, et al. Escalation of 589 Pyrethroid Resistance in the Malaria Vector Anopheles funestus Induces a Loss of Efficacy of 590 Piperonyl Butoxide-Based Insecticide-Treated Nets in Mozambique. J Infect Dis. 2019;220(3):467-75. doi: 10.1093/infdis/jiz139. PubMed PMID: 30923819; PubMed Central 591 592 PMCID: PMCPMC6603977. 593 26) Gichuki PM, Kamau L, Njagi K, Karoki S, Muigai N, Matoke-Muhia D, et al. Bioefficacy and 594 durability of Olyset(®) Plus, a permethrin and piperonyl butoxide-treated insecticidal net in a 3-595 year long trial in Kenya. Infectious diseases of poverty. 2021;10(1):135. Epub 2021/12/22. doi: 10.1186/s40249-021-00916-2. PubMed PMID: 34930459; PubMed Central PMCID: 596 597 PMCPMC8691082. 598 27) Lukole E, Cook J, Mosha JF, Messenger LA, Rowland M, Kleinschmidt I, et al. Protective efficacy 599 of holed and aging PBO-pyrethroid synergist-treated nets on malaria infection prevalence in 600 north-western Tanzania. PLOS Glob Public Health. 2022;2(10):e0000453. Epub 2023/03/25. doi:

north-western Tanzania. PLOS Glob Public Health. 2022;2(10):e0000453. Epub 2023/03/25. doi:

601 10.1371/journal.pgph.0000453. PubMed PMID: 36962517; PubMed Central PMCID: 602 PMCPMC10022078. 603 28) World Health Organization. World Health Organization: Report of the Fourth WHOPES Working 604 Group Meeting In Review of IR3535; KBR3023; (RS)-Methoprene 20% EC, Pyriproxifen 05% GR; 605 and Lamda-cyhalothrin 25% CS. Geneva, Switzerland: World Health Organization, 2001. 606 29) Lwetoijera DW, Harris C, Kiware SS, Killeen GF, Dongus S, Devine GJ, et al. Comprehensive 607 sterilization of malaria vectors using pyriproxyfen: a step closer to malaria elimination. Am J Trop 608 Med Hyg. 2014;90(5):852-5. Epub 2014/03/19. doi: 10.4269/ajtmh.13-0550. PubMed PMID: 609 24639296; PubMed Central PMCID: PMCPMC4015577. 610 30) Accrombessi M, Cook J, Dangbenon E, Yovogan B, Akpovi H, Sovi A, et al. Efficacy of 611 pyriproxyfen-pyrethroid long-lasting insecticidal nets (LLINs) and chlorfenapyr-pyrethroid LLINs 612 compared with pyrethroid-only LLINs for malaria control in Benin: a cluster-randomised, 613 superiority trial. Lancet. 2023;401(10375):435-46. Epub 2023/01/28. doi: 10.1016/S0140-614 6736(22)02319-4. PubMed PMID: 36706778. 615 31) Epstein A, Namuganga JF, Kamya EV, Nankabirwa JI, Bhatt S, Rodriguez-Barraquer I, et al. 616 Estimating malaria incidence from routine health facility-based surveillance data in Uganda. 617 Malar J. 2020;19(1):445. doi: 10.1186/s12936-020-03514-z. PubMed PMID: 33267886; PubMed 618 Central PMCID: PMCPMC7709253. 619 32) World Health Organization. Global plan for insecticide resistance management in malaria 620 vectors. Geneva, Switzerland: World Health Organization, 2012. 621

Figure 1: Map of study area: The study included 64 clusters across 32 districts; 2 clusters per district, one per study arm. A cluster was defined as a malaria reference centre and its target area.

Figure 2: Trial profile. LLIN=long-lasting insecticidal net. BS=blood smear. Hb=haemoglobin.

Figure 3: Malaria incidence per 1000 person-years. LLINs were distributed in waves over a period of 5 months. Malaria incidence measures cater for the staggered distribution of LLINs across the sites.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.31.24311272; this version posted August 2, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license

Table 1. Cluster-level characteristics of households, bed nets and household residents from cross-sectional surveys

		12-month	surveys	24-month surveys		
Variable	Characteristic	pyrethroid-PBO LLINs	pyrethroid- pyriproxyfen LLINs	pyrethroid-PBO LLINs	pyrethroid- pyriproxyfen LLINs	
Number of households surveyed		1771	1747	1690	1682	
Measure of crowding, mean (SD)	≥ 3 persons / sleeping rooms	55.9% (15.4%)	57.4% (17.9%)	55.9% (14.6%)	53.1% (13.7%)	
Socioeconomic index in terciles, mean (SD)	— Poorest	31.7% (22.3%)	35.6% (25.2%)	33.1% (21.9%)	33.6% (22.3%)	
	— Poor	34.1% (13.7%)	33.4% (17.5%)	32.6% (14.0%)	35.4% (14.0%)	
	—Least poor	34.2% (23.3%)	31.0% (22.4%)	34.2% (25.1%)	31.0% (21.7%)	
Household construction, mean (SD) *	—Traditional	59.5% (32.7%)	62.2% (32.8%)	50.9% (30.7%)	56.5% (29.4%)	
	— Modern	40.5% (32.7%)	37.8% (32.8%)	49.1% (30.7%)	43.5% (29.4%)	
Number of bed nets surveyed		3991	3790	3211	3095	
Where bed net was obtained, mean (SD)	—Most recent universal coverage campaign	92.4% (8.5%)	89.1% (14.2%)	87.1% (10.9%)	80.1% (18.4%)	
	— Prior universal coverage campaign	2.2% (4.8%)	2.0% (5.2%)	1.4% (2.5%)	3.2% (5.9%)	
	—Other	5.4% (5.5%)	8.9% (10.4%)	11.4% (9.3%)	16.8% (14.3%)	
Bed net obtained for free, mean (SD)		97.7% (2.7%)	96.9% (3.4%)	95.4% (5.1%)	94.1% (6.0%)	
Number of residents surveyed		8249	7940	8400	8306	
Female gender, mean (SD)		55.6% (3.9%)	54.8% (3.8%)	54.6% (3.2%)	54.2% (3.1%)	
Age categories, mean (SD)	< 5 years	19.5% (3.8%)	18.6% (3.6%)	19.1% (3.8%)	18.6% (4.2%)	
	5-15 years	33.9% (4.1%)	34.2% (5.0%)	33.6% (3.9%)	33.9% (4.5%)	
	16 years or older	46.5% (4.0%)	47.2% (3.7%)	47.4% (4.8%)	47.5% (4.6%)	

<sup>\*</sup>Houses were dassified as 'modern' (synthetic walls and roofs, eaves closed or absent) or 'traditional' (all other construction)

Table 2. Malaria incidence in residence of all ages from MRC target areas

Study arm	Baseline *			24 months post-intervention				
	Episodes of malaria	Person years of observation	Malaria incidence per 1000 PY	Episodes of malaria	Person years of observation	Malaria incidence per 1000 PY	IRR (95% CI)**	p-value
pyrethroid-PBO LLINs	16,763	24,783	676	95,898	206,211	465	reference arm	
pyrethroid-pyriproxyfen LLINs	15,621	23,162	674	90,466	192,720	469	1.06 (0.91-1.22)	0.47

<sup>\* 3</sup> months prior to completion of LLIN distribution

Table 3. Secondary outcomes assessed at 12- and 24-months post-intervention from cross-sectional surveys of MRC target areas

In dicat or	Study arm	12-month survey			24-month survey		
		n/N (%)	OR (95% CI)	p-value	n/N (%)	OR (95% CI)	p-value
LLIN ownership* in households	pyrethroid-PBO LLINs	1628/1771 (91.9%)	reference	_	1384/1690 (82.5%)	reference	_
	pyrethroid-pyriproxyfen LLINs	1571/1747 (89.9%)	0.81 (0.44-1.47)	0.48	1345/1682 (80.0%)	0.81 (0.45-1.47)	0.50
Adequate LLIN coverage† in households	pyrethroid-PBO LLINs	1060/1771 (59.9%)	reference	_	695/1690 (41.1%)	reference	-
	pyrethroid-pyriproxyfen LLINs	987/1747 (56.5%)	0.85 (0.58-1.25)	0.41	650/1682 (38.6%)	0.87 (0.56-1.36)	0.55
LLIN use‡ in household residents	pyrethroid-PBO LLINs	6121/8249 (74.2%)	reference	_	5341/8400 (63.6%)	reference	_
	pyrethroid-pyriproxyfen LLINs	6045/7940 (76.1%)	0.98 (0.54-1.79)	0.96	5117/8306 (61.6%)	0.80 (0.41-1.58)	0.52
Parasite prevalence in children 2-10 years	pyrethroid-PBO LLINs	521/2411 (21.6%)	reference	_	602/2311 (26.1 %)	reference	-
	pyrethroid-pyriproxyfen LLINs	654/2482 (26.4%)	1.49 (0.88-2.51)	0.14	651/2208 (29.5%)	1.29 (0.81-2.05)	0.29
Anaemia** prevalence in children 2-4 years	pyrethroid-PBO LLINs	385/1065 (36.2%)	reference	_	191/971 (19.7%)	reference	_
	pyrethroid-pyriproxyfen LLINs	347/1022 (34.0%)	0.88 (0.57-1.34)	0.54	178/937 (19.0%)	0.95 (0.62-1.46)	0.81


<sup>\*</sup> LLIN ownership defined as household with at least 1 LLIN

<sup>\*\*</sup> Adjusted for baseline malaria incidence; random effect at the level of the district

<sup>†</sup> Adequate LLIN coverage defined as household with at least 1 LLIN for every 2 residents

<sup>‡</sup> LLIN use defined as household resident who reported sleeping under a LLIN the prior night

<sup>\*\*</sup> Anaemia defined as haemoglobin < 11 g/dL



32 clusters randomised to pyrethroid-piperonyl butoxide LLINs 32 clusters randomised to pyrethroid-pyriproxyfen LLINs Community surveys - household recruitment Community surveys - household recruitment 12-month survey 24-month survey 12-month survey 24-month survey 2388 selected for screening 2174 selected for screening 2329 selected for screening 2238 selected for screening 185 vacant or destroyed 184 vacant or destroyed 299 vacant or destroyed 168 vacant or destroyed 374 households excluded 399 households excluded 323 households excluded 307 households excluded -300 unable to locate adult -334 unable to locate adult -250 unable to locate adult -248 unable to locate adult -65 unwilling to consent -59 unwilling to consent -74 unwilling to consent -73 unwilling to consent 1771 households enrolled 1690 households enrolled 1682 households enrolled 1747 households enrolled cluster median 53 cluster median 52 cluster median 54 cluster median 52 (range: 50-78) (range: 50-64) (range: 50-67) (range: 50-62) 1604 households with 1600 households with 1602 households with 1600 households with child aged 2-10 years child aged 2-10 years child aged 2-10 years child aged 2-10 years cluster median 50 cluster median 50 cluster median 50 cluster median 50 (range: 50-50) (range: 50-53) (range: 50-50) (range: 50-52) Clinical surveys of children aged 2-10 years Clinical surveys of children aged 2-10 years 12-month survey 24-month survey 12-month survey 24-month survey 3011 children eligible 3045 children eligible 2981 children eligible 2935 children eligible 600 children excluded 734 children excluded 499 children excluded 727 children excluded 2411 children enrolled 2311 children enrolled 2482 children enrolled 2208 children enrolled 0 missing blood smear 0 missing blood smear 0 missing blood smear 0 missing blood smear 2411 children with BS results 2311 children with BS results 2482 children with BS results 2208 children with BS results cluster median 70 cluster median 68 cluster median 73 cluster median 68 (range: 58-122) (range: 55-94) (range: 54-108) (range: 50—94) Haemoglobin testing in children aged 2-4 years Haemoglobin testing in children aged 2-4 years 12-month survey 24-month survey 12-month survey 24-month survey 1176 children eligible 1148 children eligible 1112 children eligible 1093 children eligible 109 children excluded 168 children excluded 86 children excluded 155 children excluded 1067 children enrolled 980 children enrolled 1026 children enrolled 938 children enrolled 2 missing haemoglobin 9 missing haemoglobin 4 missing haemoglobin 1 missing haemoglobin 1065 children with Hb results 971 children with Hb results 1022 children with Hb results 937 children with Hb results cluster median 32 cluster median 31 cluster median 31 cluster median 29 (range: 21-48) (range: 16-48) (range: 17-47) (range: 14-41)

